PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions.
Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results.
"This reusable suite of shared platform services enables us to both integrate with and launch new interoperable software solutions that span our customers’ workflows from discovery to submission," said Max Kanevsky, Chief Technology Officer of Certara Data Sciences Software. "Clients want easy-to-use, integrated solutions that speed time to insight for novel drug development problems," said William F. Feehery, CEO of Certara. "Certara Cloud enhances the customer experience for clients that use multiple Certara products."
Certara Cloud delivers value and unique capabilities across several areas of immediate benefit and lays the foundation for future advanced operations, including:
Certara Cloud is following a phased roll-out over 2024 with over 1,500 client-specific portals already prepared and is currently in use by fifteen of the top 30 biopharmaceutical companies. Customers are welcome to register individually for their Certara ID via https://my.certara.net/.
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at www.certara.com.
Certara Contact:
Sheila Rocchio
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alyssa Horowitz
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.39 |
Daily Change: | -0.07 -0.61 |
Daily Volume: | 1,487,086 |
Market Cap: | US$1.830B |
August 15, 2024 August 06, 2024 May 07, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB